Clinical Study

Vitamin D Receptor Gene BsmI Polymorphism in Polish Patients with Systemic Lupus Erythematosus

Beata Kaleta,1 Jarosław Bogaczewicz,2 Ewa Robak,2 Anna Sysa-Jedrzejowska,2 Małgorzata Wrzosek,3 Weronika Szubierańska,1 Piotr Mróz,1 Jacek Łukaszkiewicz,1 and Anna Woźniacka2

1 Department of Biochemistry and Clinical Chemistry, Medical University of Warsaw, 02-097 Warsaw, Poland
2 Department of Dermatology and Venereology, Medical University of Łódź, 94-017 Łódź, Poland
3 Department of Pharmacogenomics, Medical University of Warsaw, 02-097 Warsaw, Poland

Correspondence should be addressed to Beata Kaleta; kaletabeata1@gmail.com

Received 13 May 2013; Accepted 7 June 2013

Academic Editors: J. Pachucki, J. A. Rillema, and H. Tamemoto

Copyright © 2013 Beata Kaleta et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The hormonally active form of vitamin D3, 1,25(OH)2D3 (calcitriol), exerts actions through VDR receptor, which acts as a transcriptional factor. Calcitriol is an immunomodulator that affects various immune cells, and several studies link it to many autoimmune diseases. BsmI polymorphism affects the level of VDR gene transcription, transcript stability, and posttranscriptional modifications. It seems to be related to the systemic lupus erythematosus (SLE). Our study examined the characteristics of VDR gene BsmI polymorphism in Polish SLE patients and their relationship with clinical manifestations of the disease. We genotyped 62 patients with SLE and 100 healthy controls using the real-time PCR. There were no differences observed in the frequency of BsmI genotypes in SLE patients and in the control group. There was no significant correlation between BsmI genotypes and clinical symptoms of SLE, but the AA genotype correlates with higher levels of antinuclear antibodies (ANA) in this group ($r = 0.438; P = 0.002$). A larger study examining BsmI and other VDR gene polymorphisms is needed. It may allow explaining differences in the clinical picture of the disease and choosing a personalized therapy.

1. Introduction

Systemic lupus erythematosus is a chronic antibody-mediated autoimmune disorder. The etiology of SLE is still unknown, but many studies demonstrate association between the disease and genes which are crucial to immunological response [1, 2]. Active form of vitamin D, 1,25(OH)2D3, exerts action by binding to the VDR (vitamin D receptor) which acts as a ligand-dependent transcriptional factor. VDR are present not only in tissues related to calcium-phosphorus homeostasis (bone, skin, kidneys, and intestine) but also in nonclassical tissues, among others immune cells [3, 4]. The VDR protein is synthesized from a gene known as VDR which is highly polymorphic. The most significant polymorphisms for VDR activity are FokI (rs228570) and BsmI (rs1544410). BsmI polymorphism is located in intron 8 and affects the level of VDR gene transcription, transcript stability, and posttranscriptional modifications [5–10]. VDR are present in nearly all immune cells. 1,25(OH)2D3 blocks B cell differentiation and proliferation, enhances chemotactic and phagocytic capacity of macrophages, inhibits DC maturation, and modulates DC-derived cytokine and chemokine expression, by inhibiting production of IL-12, IL-23 and enhancing release of IL-10. In addition vitamin D inhibits the surface expression of MHC-II-complexed antigen and costimulatory molecules, affects T cells response, inhibits production of Th1 cytokines (IL-2, IFN-γ), Th17 cytokines (IL-17, IL-21), and stimulates Th2 cytokine production (IL-4). Moreover this hormone reduces Th induction of immunoglobulin (IgM, IgG) production by B cells [11–21]. Moreover immune cells express enzymes, that is, 25-hydroxylase, 1 α-hydroxylase, which are needed to generate bioactive 1,25(OH)2D3 [22, 23]. All of this suggest that 1,25(OH)2D3 plays a key role in immune homeostasis. It is known that the deficiency of active
Asian patients has been reported [1,2,34,41,42]. Gene polymorphisms and systemic lupus erythematosus in laboratory profile in Polish patients with SLE. The relationship between this polymorphism and clinical and population, our study was conducted in order to evaluate the contribution of BsmI genotypes between Chinese and European populations. The study involved 62 Polish patients (57 women, 5 men) with SLE treated at the Department of Dermatology and Venereology, Medical University of Łódź, Poland. All patients fulfilled at least four out of eleven criteria for SLE classification [43]. This group was selected randomly. 100 healthy subjects (63 women, 37 men) served as controls. They did not meet criteria for SLE and other autoimmune diseases. Short characteristic of SLE patients and control subjects is presented in Table 1.

As the literature data indicates differences in the distribution of BsmI genotypes between Chinese and European population, our study was conducted in order to evaluate relationship between this polymorphism and clinical and laboratory profiles in Polish patients with SLE.

2. Materials and Methods

The study involved 62 Polish patients (57 women, 5 men) with SLE treated at the Department of Dermatology and Venereology, Medical University of Łódź, Poland. All patients fulfilled at least four out of eleven criteria for SLE classification [43]. This group was selected randomly. 100 healthy subjects (63 women, 37 men) served as controls. They did not meet criteria for SLE and other autoimmune diseases. Short characteristic of SLE patients and control subjects is presented in Table 1.

Genomic DNA was extracted from peripheral full blood using ”Blood Mini” kit from A&A Biotechnologies and following the protocol of producer. VDR BsmI genotyping was performed by real-time polymerase chain reaction (RT-PCR, LightCycler, Roche) with SimpleProbe (TIB MOLBIOL) melting-curve analysis in accordance with the conditions showed in Table 2.

It enables to identify individual BsmI genotypes (polymorphic variants) of vitamin D receptor gene. The genotypes were classified as homozygote major allele (GG), heterozygote (GA) and homozygote minor alleles (AA).

Statistical analyses were performed using Statistica 10.0 (StatSoft Inc.). To compare the frequency of genotypes and alleles of VDR BsmI polymorphism in patients with SLE and control group, the Freeman–Halton extension of Fisher’s exact test and Fisher’s exact test were used. Correlation analysis of BsmI genotypes with clinical manifestations and laboratory profiles of SLE was performed using Spearman’s Rank Correlation Test. Hardy–Weinberg equilibrium (HWE) was determined by Pearson’s $\chi^2$ goodness-of-fit test. Differences were considered statistically significant at a $P$ value < 0.05.

The study was approved by the Local Ethics Committee (no. RNN/67/08/KE).

3. Results and Discussion

Table 3 presents VDR BsmI genotypes and alleles in patients with SLE and in control group. The distribution of genotypes was 53% for GG, 32% for GA, and 14% for AA in patients with SLE and, respectively, 41%, 42%, and 17% in control group. There was no statistically significant difference between these groups ($P = 0.309$). The allelic distribution of G and A was similar within the two groups ($P = 0.188$). The genotype frequencies were consistent with HWE in patients and controls ($\chi^2 = 3.60; P = 0.058$ and $\chi^2 = 1.18; P = 0.277$, resp.).

The relationship between VDR BsmI genotypes and clinical manifestation or laboratory profiles of SLE is demonstrated in Table 4. There is no relationship between BsmI genotypes and clinical symptoms of SLE, but it was shown that AA genotype of BsmI polymorphism is in correlation with higher titer of antinuclear antibodies’ ($r = 0.438; P = 0.002$) (Table 5).

Vitamin D exerts several immunomodulatory effects and thus may play a role in the course of autoimmune diseases. Its active hormonal form 1,25(OH)$_2$D$_3$, among others, blocks B cell proliferation, differentiation, and immunoglobulin production [7–13].

Numerous studies have shown that vitamin D deficiency may increase the risk of autoimmune diseases such as systemic lupus erythematosus [16–32]. The role of vitamin D receptor gene polymorphism can modify the immunomodulatory action of vitamin D and has an impact on the clinical picture of SLE. It has been demonstrated that VDR gene BsmI polymorphism is a genetic marker of systemic lupus erythematosus in Asian patients [1, 2, 40–42]. In our study we analyzed vitamin D receptor gene BsmI polymorphism in the Polish patients with SLE. We did not find statistically significant differences in the frequency of BsmI genotypes and alleles in SLE patients and healthy controls. Our observations are consistent with the findings of Mostowska et al. [44], Monticielo et al. [45], and Sakulpipatsin et al. [46] who demonstrated no association of the BsmI polymorphism with the development of SLE in the Brazilian, Iranian, Thai, and European populations. However, this polymorphism was associated with lupus nephritis in a Japanese population [41].

Different results of various studies may be due to group size, gene–gene interactions, and environmental factors. Our study showed that AA genotype of BsmI polymorphism is associated with higher concentration of antinuclear antibodies (ANA) in patients with SLE. However it is difficult to explain this phenomenon as it is generally known that ANA titer does not correlate with the disease activity and is not considered as a valuable prognostic factor. It is possible that BsmI polymorphism changes the immunomodulatory action of 1,25(OH)$_2$D$_3$ resulting in modified antibodies production by activated B cells.

4. Conclusions

The BsmI genotype frequencies in Polish patients with SLE are not different from healthy controls. There is no significant correlation of this polymorphism and clinical symptoms of systemic lupus erythematosus. Our data did not reveal that in Polish patients with SLE VDR gene BsmI polymorphism could be regarded as a genetic marker of the disease. AA genotype of BsmI polymorphism promotes a higher concentration of ANA in SLE patients but future studies are needed to confirm the validity of these observations.
Table 2: Real-time PCR reaction conditions.

| Parameter                  | Denat. | Cycling | Program | Melting | Cooling |
|----------------------------|--------|---------|---------|---------|---------|
| Analysis mode              | None   |         |         |         |         |
| Cycles                     | 1      | 45      | 1       | 1       |         |
| Segment                    | 1      | 1       | 2       | 3       | 1       |
| Target ['C]                | 95     | 95      | 60      | 72      | 95      |
| Hold [hh:mm:ss]            | 00:10:00 | 00:00:10 | 00:00:15 | 00:00:30 | 00:02:00 | 00:00:00 | 00:00:30 |
| Ramp rate ['C/s]           | 4.4    | 4.4     | 2.2     | 4.4     | 4.4     | 1.5     | —       | 1.5     |
| Acquisition mode           | None   | None    | Single  | None    | None    | Continu. |         |
| Acquisition per ['C]       |        |         |         |         |         |         | 3       |

Table 3: Distribution of VDR BsmI genotypes and alleles in patients with SLE and healthy controls.

| Group          | Genotype (%) | Alleles |        |
|----------------|--------------|---------|--------|
| SLE1 (n = 62)  | GG (wt) 33 (53) | GA 20 (32) | AA (mt) 9 (14) |
|                | G 86 (0.7)   | A 38 (0.3)  |
| Control2 (n = 100) | GG 41 (41)   | GA 42 (42)  | AA 17 (17)  |
|                | G 123 (0.6)  | A 77 (0.4)  |
| Statistics*    | X^2 = 2.35; df = 2; P = 0.309 |

* Freeman–Halton extension of Fisher’s exact test and Fisher’s exact test.

Table 4: Relationship between BsmI genotypes and clinical manifestation or laboratory profiles of SLE.

| Correlated variables                  | GG n = 33 | GA n = 20 | AA n = 9 | Total N = 62 | P* |
|---------------------------------------|-----------|-----------|----------|--------------|----|
| Malar rash                            | 14/33     | 13/20     | 6/9      | 33/62        | 0.216 |
| Discoid rash (DLE)                    | 4/33      | 1/20      | 0/9      | 5/62         | 0.549 |
| Photosensitivity                      | 6/33      | 0/20      | 3/9      | 9/62         | 0.145 |
| Oral ulcer                            | 5/33      | 0/20      | 1/9      | 6/62         | 0.171 |
| Arthritis/arthritisalgia              | 30/33     | 18/20     | 9/9      | 57/62        | 1.000 |
| Serositis                             | 3/33      | 1/20      | 1/9      | 5/62         | 0.840 |
| Renal disorder                        | 5/33      | 2/20      | 1/9      | 8/62         | 0.876 |
| Neuropsychiatric disorder             | 7/33      | 4/20      | 2/9      | 13/62        | 1.000 |
| Hematologic disorder                  |           |           |          |              |     |
| (i) Anemia                            | 9/33      | 2/20      | 2/9      | 13/62        | 0.348 |
| (ii) Leukopenia                       | 16/33     | 6/20      | 6/9      | 28/62        | 0.372 |
| (iii) Lymphopenia                     | 1/33      | 1/20      | 0/9      | 2/62         | 1.000 |
| (iv) Thrombocytopenia                 | 9/33      | 2/20      | 0/9      | 11/62        | 0.115 |
| Immunologic disorder                  |           |           |          |              |     |
| (i) Anti-dsDNA                        | 9/33      | 1/20      | 2/9      | 12/62        | 0.124 |
| (ii) Anti-5m                           | 0/33      | 0/20      | 0/9      | 0/62         | 1.000 |
| ANA presence                          | 29/33     | 18/20     | 8/9      | 55/62        | 1.000 |

* Freeman–Halton extension of Fisher’s exact test and Fisher’s exact test.

Table 5: Correlation between BsmI genotypes and higher titer of antinuclear antibodies in SLE patients.

| Correlated variables* | BsmI genotype versus ANA/L | r: 0.438 | P: 0.002 |

* Spearman’s Rank Correlation Test, BsmI genotypes (ranks): 0: GG, 1: GA, and 2: AA; ANA/L: antinuclear antibodies per liter; r: Spearman’s rank correlation coefficient.

Abbreviations

ANA: Antinuclear antibodies
DC: Dendritic cells
HWE: Hardy-Weinberg equilibrium
IF: Interferon
IgG: Immunoglobulin G
IgM: Immunoglobulin M
IL: Interleukin
MHC: Major histocompatibility complex
RT-PCR: Real-time polymerase chain reaction
SLE: Systemic lupus erythematosus
Th: T helper cell
VD: Vitamin D
VDR: Vitamin D receptor.

Conflict of Interests

The authors declare no conflict of interests.

Acknowledgment

This work was supported by Grant no. DEC-2011/01/D/NZ5/00316 from the National Science Centre, Poland.

References

[1] H.-S. Lee and S.-C. Bae, “What can we learn from genetic studies of systemic lupus erythematosus? Implications of genetic heterogeneity among populations in SLE,” *Lupus*, vol. 19, no. 12, pp. 1452–1458, 2010.

[2] K. L. Moser, J. A. Kelly, C. J. Lessard, and J. B. Harley, “Recent insights into the genetic basis of systemic lupus erythematosus,” *Genes and Immunity*, vol. 10, no. 5, pp. 373–379, 2009.

[3] D. Bikle, “Nonclassic actions of vitamin D,” *Journal of Clinical Endocrinology and Metabolism*, vol. 94, no. 1, pp. 26–34, 2009.

[4] A. Verstuyf, G. Carmeliet, R. Bouillon, and C. Mathieu, “Vitamin D: a pleiotropic hormone,” *Kidney International*, vol. 78, no. 2, pp. 140–145, 2010.

[5] K.-I. Miyamoto, R. A. Kesterson, H. Yamamoto et al., “Structural organization of the human vitamin D receptor chromosomal gene and its promoter,” *Molecular Endocrinology*, vol. 11, no. 8, pp. 1165–1179, 1997.

[6] A. G. Uitterlinden, Y. Fang, J. B. J. Van Meurs, H. A. P. Pols, and J. P. T. M. Van Leeuwen, “Genetics and biology of vitamin D receptor polymorphisms,” *Gene*, vol. 338, no. 2, pp. 143–156, 2004.

[7] H. Arai, K.-I. Miyamoto, Y. Taketani et al., “A vitamin D receptor gene polymorphism in the translation initiation codon: effect on protein activity and relation to bone mineral density in Japanese women,” *Journal of Bone and Mineral Research*, vol. 12, no. 6, pp. 915–921, 1997.

[8] G. K. Whitfield, L. S. Remus, P. W. Jurutka et al., “Functionally relevant polymorphisms in the human nuclear vitamin D receptor gene,” *Molecular and Cellular Endocrinology*, vol. 177, no. 1-2, pp. 145–159, 2001.

[9] E. van Etten, L. Verlinden, A. Giulietti et al., “The vitamin D receptor gene FokI polymorphism: functional impact on the immune system,” *European Journal of Immunology*, vol. 37, no. 2, pp. 395–405, 2007.

[10] L. A. Crofts, N. A. Morrison, N. Dudman, and J. A. Eisman, “Differential expression of VDR gene alleles,” *Journal of Bone and Mineral Research*, vol. 11, supplement 1, p. S208, 1996.

[11] F. Baeke, H. Korf, L. Overbergh et al., “Human T lymphocytes are direct targets of 1,25-dihydroxyvitamin D3 in the immune system,” *Journal of Steroid Biochemistry and Molecular Biology*, vol. 121, no. 1-2, pp. 221–227, 2010.

[12] A. Boonstra, F. J. Barrat, C. Crain, V. L. Heath, H. F. J. Savelkoul, and A. O’Garra, “1α,25-Dihydroxyvitamin D3 has a direct effect on naive CD4+ T cells to enhance the development of Th2 cells,” *Journal of Immunology*, vol. 167, no. 9, pp. 4974–4980, 2001.

[13] J. Tang, R. Zhou, D. Luger et al., “Calcitriol suppresses antirenal autoimmunity through inhibitory effects on the Th17 effector response,” *Journal of Immunology*, vol. 182, no. 8, pp. 4624–4632, 2009.

[14] L. E. Jeffery, F. Burke, M. Mura et al., “1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3,” *Journal of Immunology*, vol. 183, no. 9, pp. 5458–5467, 2009.

[15] B. D. Mahon, A. Wittko, V. Weaver, and M. T. Cantorna, “The targets of vitamin D depend on the differentiation and activation status of CD4 positive T cells,” *Journal of Cellular Biochemistry*, vol. 89, no. 5, pp. 922–932, 2003.

[16] S. Chen, G. P. Sims, X. C. Xiao, Y. G. Yue, S. Chen, and P. E. Lipsky, “Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation,” *Journal of Immunology*, vol. 179, no. 3, pp. 1634–1647, 2007.

[17] A.-K. Shirakawa, D. Nagakubo, K. Hieshima, T. Nakayama, Z. Jin, and O. Yoshie, “1α,25-Dihydroxyvitamin D3 induces CCR10 expression in terminally differentiating human B cells,” *Journal of Immunology*, vol. 180, no. 5, pp. 2786–2795, 2008.

[18] H. Xu, A. Soruri, R. K. H. Gieseler, and J. H. Peters, “1,25-Dihydroxyvitamin D3 exerts opposing effects to IL-4 on MHC class-II antigen expression, accessory activity, and phagocytosis of human monocytes,” *Scandinavian Journal of Immunology*, vol. 38, no. 6, pp. 535–540, 1993.

[19] G. Penna and L. Adorini, “1α,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation,” *Journal of Immunology*, vol. 164, no. 5, pp. 2405–2411, 2000.

[20] A. Berer, J. Stöckl, O. Majdic et al., “1,25-Dihydroxyvitamin D3 inhibits dendritic cell differentiation and maturation in vitro,” *Experimental Hematology*, vol. 28, no. 5, pp. 575–583, 2000.

[21] M. C. Gauazzi, C. Purificato, K. Donato et al., “Suppressive effect of 1α,25-dihydroxyvitamin D3 on type I IFN-mediated monocyte differentiation into dendritic cells: impairment of functional activities and chemotaxis,” *Journal of Immunology*, vol. 174, no. 1, pp. 270–276, 2005.

[22] D. M. Provvedini, C. D. Tsoukas, L. J. Defos, and S. C. Manolagas, “1,25-Dihydroxyvitamin D3 receptors in human leukocytes,” *Science*, vol. 221, no. 4616, pp. 1181–1183, 1983.

[23] C. M. Veldman, M. T. Cantorna, and H. F. DeLuca, “Expression of 1,25-dihydroxyvitamin D3 receptor in the immune system,” *Archives of Biochemistry and Biophysics*, vol. 374, no. 2, pp. 334–338, 2000.

[24] S.-W. Guo, V. L. Magnuson, J. J. Schiller, X. Wang, Y. Wu, and S. Ghosh, “Meta-analysis of vitamin D receptor polymorphisms and type 1 diabetes: a HuGE review of genetic association studies,” *American Journal of Epidemiology*, vol. 164, no. 8, pp. 711–724, 2006.

[25] D. B. Mory, E. R. Rocco, W. L. Miranda, T. Kasamatsu, F. Crispim, and S. A. Dib, “Prevalence of vitamin D receptor gene polymorphisms FokI and BsmI in Brazilian individuals with type 1 diabetes and their relation to β-cell autoimmunity and to remaining β-cell function,” *Human Immunology*, vol. 70, no. 6, pp. 447–451, 2009.

[26] B. Lüttorin, P. Blom, A. Schölin et al., “Lower levels of plasma 25-hydroxyvitamin D among young adults at diagnosis of autoimmune type 1 diabetes compared with control subjects:...
results from the nationwide Diabetes Incidence Study in Sweden (DISS)." Diabetologia, vol. 49, no. 12, pp. 2847–2852, 2006.

[27] E. Sundqvist, M. Bārnhilm, L. Alfredsson, J. Hillert, T. Olsson, and I. Kockum, "Confirmation of association between multiple sclerosis and CYP27B1," European Journal of Human Genetics, vol. 18, no. 12, pp. 1349–1352, 2010.

[28] C. E. Hayes, M. T. Cantorna, and H. F. DeLuca, "Vitamin D and multiple sclerosis," Experimental Biology and Medicine, vol. 216, no. 1, pp. 21–27, 1997.

[29] K. L. Munger, L. I. Levin, B. W. Hollis, N. S. Howard, and A. Ascherio, "Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis," Journal of the American Medical Association, vol. 296, no. 23, pp. 2832–2838, 2006.

[30] J. Smolders, P. Menheere, A. Kessels, J. Dамoiseaux, and R. Hupperts, "Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis," Multiple Sclerosis, vol. 14, no. 9, pp. 1220–1224, 2008.

[31] C. Gómez-Vaquero, J. Fiter, A. Enjuanes, X. Nogués, A. Diez-Pérez, and J. M. Nolla, "Influence of the BsmI polymorphism of the vitamin D receptor gene on rheumatoid arthritis clinical activity," Journal of Rheumatology, vol. 34, no. 9, pp. 1823–1826, 2007.

[32] Y. H. Lee, S.-C. Bae, S. J. Choi, J. D. Ji, and G. G. Song, "Associations between vitamin D receptor polymorphisms and susceptibility to rheumatoid arthritis and systemic lupus erythematosus: a meta-analysis," Molecular Biology Reports, vol. 38, no. 6, pp. 3643–3651, 2011.

[33] A. Maalej, E. Petit-Teixeira, L. Michou, A. Rebai, F. Cornelis, and H. Ayadi, "Association study of VDR gene with rheumatoid arthritis in the French population," Genes and Immunity, vol. 6, no. 8, pp. 707–711, 2005.

[34] C.-M. Huang, M.-C. Wu, J.-Y. Wu, and F.-J. Tsai, "Association of vitamin D receptor gene BsmI polymorphisms in Chinese patients with systemic lupus erythematosus," Lupus, vol. 11, no. 1, pp. 31–34, 2002.

[35] C. Vollmert, T. Illig, J. Altmüller et al., "Single nucleotide polymorphism screening and association analysis—exclusion of integrin β7 and vitamin D receptor (chromosome 12q) as candidate genes for asthma," Clinical and Experimental Allergy, vol. 34, no. 12, pp. 1841–1850, 2004.

[36] Y. Ozaki, S. Nomura, M. Nagahama, C. Yoshimura, H. Kagawa, and S. Fukuhara, "Vitamin-D receptor genotype and renal disorder in Japanese patients with systemic lupus erythematosus," Nephron, vol. 85, no. 1, pp. 86–91, 2000.